953
Views
19
CrossRef citations to date
0
Altmetric
Editorial

Blood-based proteomics for personalized medicine: examples from neurodegenerative disease

Pages 1-8 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Michel Prudent, Jean-Daniel Tissot & Niels Lion. (2011) Proteomics of blood and derived products: what’s next?. Expert Review of Proteomics 8:6, pages 717-737.
Read now
Edna Grünblatt. (2008) Commonalities in the genetics of Alzheimer’s disease and Parkinson’s disease. Expert Review of Neurotherapeutics 8:12, pages 1865-1877.
Read now

Articles from other publishers (15)

Hassan Rahmoune & Paul C. Guest. 2018. Investigations of Early Nutrition Effects on Long-Term Health. Investigations of Early Nutrition Effects on Long-Term Health 221 229 .
Hyun Jung Lee, Jae Hyun Kim, Seung Won Kim, Hyun Ah Joo, Hye Won Lee, You Sun Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Young-Ho Kim & Jae Hee Cheon. (2017) Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease. Digestive Diseases and Sciences 62:8, pages 1953-1962.
Crossref
Kewal K. JainKewal K. Jain. 2017. The Handbook of Biomarkers. The Handbook of Biomarkers 463 610 .
Djuro Josić & Uroš Andjelković. 2016. Personalized Medicine. Personalized Medicine 179 218 .
Silvia Mandel & Amos D. Korczyn. 2013. Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future 95 140 .
Anna Vaiopoulou, Maria Gazouli, George Theodoropoulos & George Zografos. (2012) Current Advantages in the Application of Proteomics in Inflammatory Bowel Disease. Digestive Diseases and Sciences 57:11, pages 2755-2764.
Crossref
Sharawan Yadav, Anubhuti Dixit, Sonal Agrawal, Ashish Singh, Garima Srivastava, Anand Kumar Singh, Pramod Kumar Srivastava, Om Prakash & Mahendra Pratap Singh. (2012) Rodent Models and Contemporary Molecular Techniques: Notable Feats yet Incomplete Explanations of Parkinson’s Disease Pathogenesis. Molecular Neurobiology 46:2, pages 495-512.
Crossref
Silvia A. Mandel, Micaela Morelli, Ilan Halperin & Amos D. Korczyn. (2010) Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy. EPMA Journal 1:2, pages 273-292.
Crossref
Minna A. Korolainen, Tuula A. Nyman, Tero Aittokallio & Tuula Pirttilä. (2010) An update on clinical proteomics in Alzheimer’s research. Journal of Neurochemistry 112:6, pages 1386-1414.
Crossref
Shushant Jain & Andrew B. Singleton. 2010. Essentials of Genomic and Personalized Medicine. Essentials of Genomic and Personalized Medicine 700 711 .
Ira L. Goldknopf, Jennifer K. Bryson, Irina Strelets, Silvia Quintero, Essam A. Sheta, Miguel Mosqueda, Helen R. Park, Stanley H. Appel, Holly Shill, Marwan Sabbagh, Bruce Chase, Eric Kaldjian & Katerina Markopoulou. (2009) Abnormal serum concentrations of proteins in Parkinson’s disease. Biochemical and Biophysical Research Communications 389:2, pages 321-327.
Crossref
Chien-Sheng Chen, Sean Sullivan, Troy Anderson, Aik Choon Tan, Philip J. Alex, Steven R. Brant, Carmen Cuffari, Theodore M. Bayless, Monica V. Talor, C. Lynne Burek, Huan Wang, Richard Li, Lisa Wu Datta, Yuqiong Wu, Raimond L. Winslow, Heng Zhu & Xuhang Li. (2009) Identification of Novel Serological Biomarkers for Inflammatory Bowel Disease Using Escherichia coli Proteome Chip. Molecular & Cellular Proteomics 8:8, pages 1765-1776.
Crossref
KN Rithidech, L Honikel, M Milazzo, D Madigan, R Troxell & LB Krupp. (2009) Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Multiple Sclerosis Journal 15:4, pages 455-464.
Crossref
Manuel B. Graeber. (2009) Biomarkers for Parkinson's disease. Experimental Neurology 216:2, pages 249-253.
Crossref
Ilan Halperin, Micaela Morelli, Amos D. Korczyn, Moussa B. H. Youdim & Silvia A. Mandel. (2009) Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases. Neurotherapeutics 6:1, pages 128-140.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.